



Organisation  
of European  
Cancer Institutes

In collaboration with



Maria Skłodowska-Curie

**National Research  
Institute of Oncology**

# Oncology Days

 **OECD 48**

**WORKING TOGETHER TO IMPROVE  
QUALITY AND REDUCE INEQUALITIES**

# WARSAW 2026

**GENERAL ASSEMBLY AND  
SCIENTIFIC PROGRAMME**

*17 - 19 June 2026*

*Sofitel Warsaw Victoria*



**FINAL  
PROGRAMME**

## President's Welcome

*Dear OECI Members,  
Dear Colleagues and Friends*

The OECI Oncology Days represent a privileged moment for meeting, reflection, and exchange among our members, an opportunity to share achievements, discuss emerging challenges, and jointly define future priorities in the fight against cancer.

Warsaw, a city symbolizing rebirth, innovation, and resilience, offers an ideal setting to reflect on what OECI has accomplished in recent years and how we can continue to grow as a European community of cancer research and care.

For me, this meeting holds a special meaning, as it marks the conclusion of my term as President of OECI, allowing me to look back with gratitude and pride on the journey we have shared together.

Over the past three years, we have made significant progress in strengthening OECI's role as a network of excellence and a driver of European integration. Among the results I would like to highlight:

- our participation, as leaders and/or beneficiaries, in several European projects that will undoubtedly shape the future of our Organisation, with the commitment to pursue the initiatives undertaken, which will offer concrete opportunities to improve therapeutic options and the quality of life for our patients;
- the revision of standards and the expansion of the OECI Accreditation and Designation Programme, which today involves more than 60% of our Members in Europe and beyond, helping to spread a shared culture of quality and continuous improvement;
- the launch of new training and networking initiatives aimed at promoting collaboration among young researchers, clinicians, and managers of cancer centres;
- our efforts to strengthen the translational and interdisciplinary dimensions of cancer research, encouraging an increasingly integrated model of patient care and scientific innovation;
- the expansion of OECI's international dimension, with new partnerships and exchanges that have enabled us to share experiences and expertise on a global scale, setting a model to be followed in other continents.

All this would not have been possible without the dedication, competence, and vision of our Members, who represent the true strength of OECI:

*To each of you, I express my sincerest gratitude*

As my term comes to an end, I also wish to share with you my determination to continue working actively with OECI, focusing particularly on the development of international relations. I am deeply convinced that the future of our Organisation lies in its ability to build bridges between disciplines, between centres, between countries, and between continents.

The Oncology Days 2026 will therefore represent not only an opportunity to celebrate our achievements, but also to renew our commitment to a more cohesive, inclusive, and forward-looking network.

Although European institutions increasingly recognize OECI as an authoritative interlocutor in shaping cancer control policies, the next presidency will be called upon to further strengthen dialogue with both national and European authorities.

I am confident that the new OECI Presidency, under the leadership of Professor Iwona Lugowska, will continue and strengthen, the path we have embarked upon, giving new impetus to the process of integrating the activities of Europe's most prestigious cancer institutes, and extending OECI's objectives beyond European borders.

I therefore hope that the OECI Oncology Days 2026 will provide a constructive dialogue, mutual inspiration, and renewed energy in our shared goal: to ensure that cancer patients receive treatments that are ever more effective, personalised, and respectful of the dignity of each individual.

To conclude, we are immensely grateful to the Maria Skłodowska-Curie National Research Institute of Oncology for kindly offering to host this edition of the OECI Oncology Days. We hope you will enjoy the OECI Oncology Days 2026 in Warsaw, an event that celebrates the 48th Anniversary of the OECI Foundation.




**Giovanni Apolone**  
OECI President

## The OECI Board

	<b>President Chairperson OECI EU Affairs</b> Giovanni Apolone Italy
	<b>Vice-President</b> Iwona Ługowska Poland
	<b>Executive Secretary</b> Júlio Manuel Maia de Oliveira Portugal
	<b>Treasurer</b> Alfredo Budillon Italy
	<b>Elected Member</b> Christian Brands Germany
	<b>Elected Member ECO Representative</b> Maja Cemažar Slovenia
	<b>Elected Member Chairperson Gender Equality</b> Jacqueline M.L. Stouthard The Netherlands
	<b>Elected Member</b> Olga Balaoura Greece
	<b>Elected Member</b> Steven le Guill France
	<b>Elected Member OECI Young Board</b> Per Anders Sandström Sweden
	<b>Elected Member</b> Josep Taberner Spain





## Co-opted Members to the OECI Board

	<b>OECI General Manager</b> Claudio Lombardo Belgium - Italy
	<b>OECIWORLD Chairperson</b> Thierry Philip France

## Accreditation and Designation Programme

	<b>A&amp;D Board Chairperson</b> Mef Nilbert Sweden				<b>Director of Quality and Accreditation</b> Simon Oberst Denmark
---	---	---	---	---	---

## Working Groups

	<b>Biobanking, Personalised Medicine and AI</b> Olli Carpén Finland		<b>Cancer Outcomes Research WG Chairperson</b> To be appointed
	<b>Cancer Economics WG Chairperson</b> Wim H. van Harten The Netherlands		<b>OECI for Patients WG Chairperson</b> Paulina Bravo Chile

# OECI2026 ONCOLOGY DAYS

## Welcome to the Oncology Days 2026!

I'm delighted to welcome you to Warsaw for the OECI Oncology Days 2026, hosted by the Maria Skłodowska-Curie National Research Institute of Oncology. It is a privilege for our Institute, the leading comprehensive cancer centre in Poland and a proud OECI member, to bring together the European oncology community in the very heart of Central Europe.

Warsaw, the city of Maria Skłodowska-Curie, embodies the spirit of resilience, innovation, and scientific discovery. Her legacy continues to inspire generations of researchers, clinicians, and innovators across the world. Hosting this year's Oncology Days in a city that bears her name is both a tribute to her groundbreaking discoveries and a reaffirmation of our shared commitment to excellence in cancer care, research, and prevention.

The OECI Oncology Days 2026 will focus on two crucial themes: new technologies in primary and secondary prevention, and national cancer networks. These topics reflect not only the strategic priorities of OECI but also our Institute's mission to translate scientific progress into real-world impact for patients. The sessions will showcase examples of European collaboration, from innovative digital prevention tools and genomics-driven screening to the creation of interconnected oncology networks that ensure quality, equity, and access to care.

Beyond the conference halls, we hope you will also take time to experience the unique atmosphere of Warsaw: a city rebuilt from the ashes, vibrant and forward-looking, where history meets modern science, and where determination transforms vision into achievement.

I wish you an inspiring, collaborative, and memorable meeting, one that strengthens our shared mission to improve cancer care across Europe.



**Beata Jagielska**

Institut Maria Skłodowska-Curie



## The OECI Network




The OECI is a non-governmental Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping.

OECI presently comprises 176 Members, which include some of the most prominent European Comprehensive Cancer Centres.

Several major cancer centres from the Algeria, Brazil, Chile, China, Colombia, Jordan, Lebanon, Moldova, Peru, Serbia, Tanzania, Turkey, Ukraine and Viet Nam are also members of the Organisation in order to benefit from the Accreditation and Designation Programme and to be involved in the activities promoted by the Working Groups.

The OECI aim is to accelerate the application of multidisciplinary, personalised care approaches to reduce mortality and to guarantee an equitable access to care to all cancer patients.



## The OECI membership

### Algeria

- ★ Anti-Cancer Center Blida Algeria Specialized Hospital Control Against Cancer, Blida

### Austria

- ★ Comprehensive Cancer Center Vienna, Vienna

### Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Leuven Kankerinstituut (LKI), Leuven
- ★ Kortrijk Kankercentrum az groeninge, Kortrijk
- ★ Oncologisch Centrum UZBrussel, Brussels
- ★ UZ Gent Kankercentrum, Ghent
- ★ Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

### Brazil

- ★ A.C. Camargo Cancer Centre, Sao Paulo

### Bulgaria

- Multiprofile Hospital for Active Treatment Heart and Brain Pleven, Pleven
- Bulgarian Joint Cancer Network (BJCN), Varna

### Chile

- ★ Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

### China

- Jinchazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou

### Colombia

- ★ Instituto Nacional de Cancerología ESE, Bogota

### Croatia

- Klinika za tumore Klinički bolnički centar Sestre milosrdnice, Zagreb
- Coalition of Associations for Healthcare, Zagreb

### Cyprus

- ★ German Oncology Center (GOC), Limassol
- Bank of Cyprus Oncology Centre, Nicosia

### Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Fakultní nemocnice v Motole, Prague
- Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

### Denmark

- ★ Aarhus Universitetshospital, Aarhus
- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Department of oncology Rigshospitalet, Copenhagen
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Department for cancer treatment, Herlev and Gentofte Hospital, Hellev
- Odense Universitetshospital, Odense
- Aalborg Universitetshospital, Aalborg
- Zealand University Hospital, Køge

### Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- ★ North Estonia Medical Centre, Tallinn
- ★ AS Ida-Tallinna Keskaigla, Tallinn

### Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Syöpäkeskus Tampereen Yliopistollinen Sairaala, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu
- ★ Kansallinen syöpäkeskus FICAN, Helsinki

### France

- ★ Centre Léon Bérard, Lyon
- ★ Gustave Roussy, Villejuif
- ★ Institut Curie, Paris
- ★ Centre Jean Perrin, Clermont-Ferrand
- ★ Institut Paoli – Calmettes, Marseille

- ★ Institut du Cancer de Montpellier (ICM), Montpellier

- ★ Institut Universitaire du Cancer de Toulouse-OncoPole, Toulouse

- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris

- ★ Cancer Institute AP-HP. Nord - Université Paris Cité, Paris

- ★ Institut du cancer Paris CARPEM AP-HP.Centre-Université Paris Cité, Paris

- ★ Centre François Baclesse, Caen

- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain

- ★ Centre de lutte contre le cancer Eugène Marquis, Rennes

- ★ Centre Oscar Lambret, Lille

- ★ Institut Bergonié, Bordeaux

- ★ Centre Henri Becquerel, Rouen

- ★ Centre Antoine Lacassagne, Nice

- ★ Institut Godinot, Reims

- ★ Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon

- ★ Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy

- ★ Institut du Cancer – AP-HP. Université Paris-Saclay, Villejuif

- ★ Institut Sainte Catherine, Avignon

### Germany

- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden
- Charité Comprehensive Cancer Center, Berlin
- Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt
- Comprehensive Cancer Center München, Munich
- Bayerisches Zentrum für Krebsforschung (BZKF), Erlangen

### Greece

- ★ General Oncology Hospital of Athens “Saint Savvas”, Athens
- General Oncology Hospital of Pireaus Metaxa, Pireaus
- Hellenic Cancer Federation -ELLOK, Athens

### Hungary

- ★ Országos Onkológiai Intézet, Budapest
- National Korányi Institute for Pulmonology, Budapest

### Iceland

- ★ Landspítali, Reykjavík

### Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont RCSI Cancer Centre, Dublin
- ★ HSE West North West, University of Galway Cancer Centre, Galway
- ★ Cork University Hospital/University College Cork, Cork
- ★ St Vincent's UCD Cancer Centre, Dublin
- ★ Mater Private Network, Dublin
- ★ The Mater Misericordiae University Hospital, Dublin
- Mid-Western Cancer Centre, Limerick
- Irish Cancer Society, Dublin

### Italy

- ★ Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genoa
- ★ Istituto Europeo di Oncologia, Milan
- ★ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
- ★ Istituto Nazionale Tumori IRCCS “Fondazione G.Pascale” (INT-Pascale), Naples
- ★ Istituto Nazionale Tumori Regina Elena, Rome
- ★ IRCCS Ospedale San Raffaele (OSR), Milan
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padua
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologia Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milan)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Turin)
- ★ ASST Spedali Civili di Brescia (SCH), Brescia
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- ★ Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- ★ Fondazione Poliambulanza, Brescia
- ★ Fondazione IRCCS Policlinico San Matteo, Pavia
- ★ IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
- Istituto Dermatologico San Gallicano, Rome
- Federazione italiana delle Associazioni di Volontariato in Oncologia (FAVO), Rome

### Spain

- ★ Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)
- ★ Vall d'Hebron Barcelona Campus Hospitalari, Barcelona
- ★ Cancer Center Clínica Universidad de Navarra, Pamplona
- ★ Fundación Jiménez Díaz University Hospital, Madrid
- ★ Clinic Barcelona Comprehensive Cancer Centre, Barcelona
- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- ★ Institut d'Oncologia de la Catalunya Sud Hospital Universitari Sant Joan de Reus, Reus
- ★ Centro Integral Oncológico Clara Campal, Madrid
- ★ Hospital Universitario 12 de Octubre, Madrid
- ★ Hospital Universitario La Paz, Madrid
- ★ Hospital Universitario Ramon Y Cajal, Madrid
- ★ Hospital Universitario Clínico San Carlos, Madrid
- ★ Hospital Clínico Universitario de Valencia (Departamento de Salud Clínico-Malvarrosa), Valencia
- ★ Hospital General Universitario Gregorio Marañón, Madrid
- ★ Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda
- ★ Fundació de Gestió Sanitària de l'Hospital de La Santa Creu i Sant Pau - Campus Sant Pau – Puigvert, Barcelona
- Hospital Universitario Virgen de la Victoria, Malaga
- La Princesa University Hospital, Madrid
- Hospital Universitario y Politécnico La Fe, Valencia

### Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Uppsala University Hospital, Uppsala
- ★ Sahlgrenska University Hospital, Göteborg
- ★ Linköping Comprehensive Cancer Center, Linköping
- ★ Norrlands Universitetssjukhus, Umeå
- University Hospital of Örebro - Örebro Comprehensive Cancer Centre, Örebro
- Nätverket mot cancer, Stockholm

### Switzerland

- Comprehensive Cancer Center Zürich (CCZ), Zurich

### Tanzania

- The Aga Khan Hospital, Dar es Salaam, Dar es Salaam

### The Netherlands

- ★ OncoZON Cancer Network, Maastricht
- ★ Netherlands Cancer Institute, Amsterdam
- ★ Erasmus MC Cancer Institute, Rotterdam
- ★ Maastricht University Medical Centre+, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- ★ Rijnstate, Arnhem
- ★ Radboudumc Centrum voor Oncologie, Nijmegen
- ★ IKNL Integraal Kankercentrum Nederland, Utrecht

### Turkey

- ★ Anadolu Sağlık Merkezi, Kocaeli
- Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Izmir
- Türkiye Cancer Institute-TKE, Istanbul

### Ukraine

- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv
- National Cancer Institute, Kyiv

### United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cancer Research UK Cambridge Centre, Cambridge
- Velindre Cancer Service - part of Velindre University NHS Trust, Cardiff

### Viet Nam

- Bệnh viện K, Hanoi



**Maria Skłodowska-Curie National Research Institute of Oncology (MSCI)** is the largest and one of the most important comprehensive oncology centers in Central Europe. The Institute conducts therapeutic, research and development, educational, and organizational activities in oncology. Its main headquarters is located in Warsaw, with regional branches in Kraków and Gliwice. The entire institution employs over 5,800 people, including more than 1,300 doctors, 1,400 nurses, and over 220 research staff. In 2024 alone, the Warsaw headquarters of the National Institute of Oncology recorded over 100,000 hospitalizations, more than 300 major surgeries, and almost 500,000 outpatient visits.

Historically, the Institute originated from the Radium Institute established at the initiative of Marie Skłodowska-Curie in the 1920s. Destroyed during World War II and rebuilt afterward, it grew into a national leader in cancer treatment, research and epidemiology. In the 1950', the Cancer Control Program was developed, which encompassed the expansion of scientific research—both basic and clinical—along with cancer epidemiology and prevention, as well as the creation of an oncology network. A key element was the establishment of the Central (later National) Cancer Registry in 1952.

Cancer Prevention Center provides counseling, screening programs and education focused on reducing cancer risk and detecting disease at its earliest stages. It hosts prevention programs for colorectal, cervical, breast and skin cancers and participates in international initiatives such as the Nordic-European Initiative on Colorectal Cancer and the European Polyp Surveillance Trial. The Center operates in a purpose-built facility equipped with state-of-the-art technology and staffed by specialists trained in preventive oncology.



Clinically, the Institute provides comprehensive diagnostic and therapeutic services across organ-oriented departments staffed by highly trained specialists. Each department provides the full range of combined treatment, including surgery, radiotherapy and systemic therapy, offering unique opportunities for clinical research integrated with patient care. The Warsaw branch alone offers more than 700 beds and treats the largest number of cancer patients in the country.

The Institute conducts more than 600 clinical trials, including many early-phase studies carried out in the Early-Phase Clinical Trials Unit (EPU), the first such dedicated oncology facility in Poland. The EPU is equipped and staffed to conduct First-in-Human, proof-of-concept, dose-escalation, bioavailability and drug-interaction studies according to international standards.

The Institute holds the status of a reference center for the treatment of rare adult solid cancers as a member of EURACAN (European Reference Network on Rare Adult Solid Cancers), operating under the aegis of the European Commission. MSCI is also a member of the Organization of European Cancer Institutes (OECI). Its experts actively contribute to international oncology development efforts, cooperating with organizations such as ESMO, EORTC, ESTRO, ESSO, ESO, ASCO, IARC, EACR, and AACR, which enables the co-creation of European and global oncology care standards.

A major area of scientific activity includes research on genetic and epigenetic mechanisms responsible for cancer development. Projects focus on the role of epigenetics and microRNAs, identification of novel therapeutic targets, and analysis of genetic predisposition to cancers of the breast, thyroid, lung and large bowel. Other important fields of study include population-based assessments of individuals at increased genetic risk and the prevalence of hereditary cancer syndromes. The Institute also develops murine models to test novel targeted therapies. Molecular markers are studied for their diagnostic and prognostic value, especially in lymphomas, soft tissue sarcomas, gliomas, meningiomas, and cancers of the lungs, large bowel, ovaries and vulva. Additional work includes the detection of tumor cells in body fluids and development of genetic profiles for laboratory animals used in modeling.

In 2024, MSCI carried out over 60 research projects as part of the Thematic Scientific Research and Development Plan, as well as numerous projects funded from external sources, including the National Science Centre, the National Centre for Research and Development, the Medical Research Agency, the European Commission, and the U.S. National Institutes of Health. The Institute also plays a key role in educating medical professionals – it conducts specialization programs, postgraduate training, and operates a doctoral school. It supports the development of young scientists through scholarship and grant programs, ensuring knowledge transfer and a high level of professional competence. Additionally, the Institute hosts the Student Onco-Forum, the first organization of its kind in Poland run by medical students, which supports their scientific development and promotes oncology as a career path.

The Institute also plays a key role in educating medical professionals – it conducts specialization programs, postgraduate training, and operates a doctoral school. It supports the development of young scientists through scholarship and grant programs, ensuring knowledge transfer and a high level of professional competence. Additionally, the Institute hosts the Student Onco-Forum, the first organization of its kind in Poland run by medical students, which supports their scientific development and promotes oncology as a career path.

The Institute also plays a strategic role in Poland's healthcare system as the coordinator and implementer of the National Oncology Strategy and as the National Monitoring Center for the implementation of the National Oncology Network. The National Cancer Registry, which is the main source of epidemiological data on cancer in Poland, also operates within the Institute. Furthermore, the Institute develops and implements national diagnostic and therapeutic guidelines in oncology.

The vision of The Institute is to further strengthen its position as the national leader in oncology and to become a leading oncology center in Central and Eastern Europe, through the integration of clinical, scientific, and educational activities in line with the highest international standards.

## Oncology Days Warsaw - Timetable

## Oncology Days Warsaw - Timetable

	16 June 2026	17 June 2026	
MORNING	<b>A&amp;D Board Meeting</b> 11.00 – 13.00  (Restricted to A&D Board Members)	<b>Accreditation &amp; Designation Session 1</b> <b>Current developments and excellent practices from our accredited Centres</b> 08.45 – 10.45	
		Coffee Break	
		<b>Accreditation &amp; Designation Session 2</b> <b>More excellent practices from our accredited Centres</b> 11.00 – 13.00	
	Lunch	Lunch	
AFTERNOON	<b>OECI Board &amp; Extended Board Meeting</b> 14.00 – 18.00  (Restricted to OECI Board and Extended Board Members)	<b>OECI for Patients WG Session</b> 14.00 – 16.00	<b>Cancer Economics WG Session</b> 14.00 – 16.00
		Coffee Break	
		<b>EUonQoL Session</b> 16.30 – 18.30	<b>WG Fusion Session</b> 16.30 – 18.30
EVENING	Board Dinner	19.30 - Welcome Reception	

	18 June 2026	19 June 2026	
MORNING	<b>Scientific Conference Session 1</b> <b>New technology on Precision Prevention</b> 08.45 – 10.45	<b>General Assembly Administrative Session</b> 08.00 – 10.15 (Vote restricted to Delegates of OECI Full Members present or represented)	MORNING
		Coffee Break	
	<b>Scientific Conference Session 2</b> <b>National Cancer Networks</b> 11.00 – 13.00	<b>Open Discussion with Members &amp; close of the 2026 G.A.</b> 10.30 – 13.00 (Restricted to Delegates of OECI Members)	
	Lunch	Lunch	
AFTERNOON	<b>OECI Young Network Session</b> 14.00 – 16.00	<b>OECI A&amp;D Auditors Session</b> 14.00 – 16.00	AFTERNOON
	Coffee Break		
	<b>CCI4EU – Final Report and Expectations on Capacity Building Session</b> 16.30 – 17.30		
	<b>OECI Participation to 2026 and 2027 European Commission calls</b> 17.30 – 18.30		
EVENING	20.00 Gala Dinner Kubicki Arcades of the Royal Castle & Ceremony A&D Certificates		EVENING

## Accreditation and Designation Session 1

June 17

08.45 - 10.45

### Current developments and excellent practices from our accredited centres

In this session we give a brief overview of the state of play of the A&D programme, outlining the growth and development of the programme. We focus particularly on the accreditation of Cancer Networks which are an important growth area in Europe, in terms of cancer structures to deliver consistent high quality. We then continue with a selection of excellent practices from our accredited centres in areas of diagnosis and treatment. These have been specially selected by the A&D Board from strengths identified by audit teams from the accreditation process, and then documented with evidence of impact by the Centres.

08.45 **Strategic themes for A&D 2026-2027**

*Simon Oberst and Mef Nilbert*

09.10 **Cancer Networks and Accreditation**

*Mef Nilbert*

09.25 **Q&A**

#### Excellent Practices in accredited Centres

09.30 **Governance Structure**

*Olive Gallagher, Galway*

09.45 **Towards a sustainable culture of Quality of Care**

*Jef Vanderroost, Leuven*

10.00 **Chatbot Anne**

*Susanne Werkman, NKI-AVL*

10.15 **Multidisciplinary, Clinical Pathways and My-Care Plan**

*Berit Sunde, Karolinska*

10.30 *Coffee Break*

## Accreditation and Designation Session 2

June 17

11.00 - 13.00

### More excellent practices from our accredited centres

In this session we focus on a selection of excellent practices from our accredited Centres. These have been specially selected by the A&D Board from strengths identified by audit teams from the accreditation process, and then documented with evidence of impact by the Centres. These excellent practices are in all areas of the standards, from governance to patient empowerment, treatment to research, prevention to survivorship, early detection to education.

11.00 **Early Cancer Detection in high-risk individuals**

*Joanna Williams, The Christie*

11.15 **Molecular tumor board**

*Léon van Kempen, OncoZON Network MUMC+*

11.30 **Onco@home**

*Laura Tack, AZ Groeninge*

11.45 **Implementation of a comprehensive educational framework  
for oncology nursing practice**

*Amaya Villanueva, CU Navarra/Pamplona/Madrid*

12.00 **From Play to Practice: How Games Can Support Skills Development  
in Paramedical Professionals**

*Valérie Quevreur, APHP CARPEM*

12.15 **Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch**

*Josep Tabernero, Val D'Hebron*

12.30 **Developing an International, inclusive and integrated programme  
of cancer education**

*Rachel Chown, The Christie*

12.45 **Q&A**

13.00 *Lunch*

## Cancer Economics WG Session

June 17

14.00 - 16.00

The session of the OECI Working Group on Health/Cancer Economics will be focusing on topics related to the new WG-strategy 2026-2028. This will for instance focus on input from OECI Centres in to Real-World-Data based efficiency and HTA studies.

We will present the results on a Delphi study on how to proceed in this field and a case study illuminating the importance.

Further two cases will clarify the opportunities of Centres having a HTA unit within or close by their organisation in bringing relevant innovations swiftly to patients.

Lastly we foresee input from a renowned speaker on the status and consequences of geopolitical developments on costs and pricing of oncology medicines in the coming years.

14.00 **Opening, Introduction of program and Presentation of WG strategy 2026 -2028**

*Wim. H. van Harten*

14.10 **Strategy Socio Economic Impact of cancer**

*Michael Schlander*

14.15 **Good Practices of involving technology assessment in Cancer Centres policy:**

**A. Case FALP-Chile**

*Camilla Quirland*

**B. Case NKI**

*Valesca Retel*

14.50 **How to use real world data to inform HTA, presenting consensus on guidelines and quality:**

**A. Guidance on using Hospital based Real world data**

*Wim van Harten and Valesca Retel*

**B. Case 1. Real World data and de/escalation**

*Astrid Kramer*

**C. Case 2. Combining process mining and economic evaluation for care pathways modelling in oncology**

*Lionel Perrier*

15.30 **Expert Speaker on pricing and drug costs in view of geopolitical developments**

*Neil Grubert*

15.50 **Discussion**

## OECI for Patients WG

June 17

14.00 - 16.00

### Advancing meaningful Patient and Public Partnership (PPP) in global cancer care and research

The session aims at strengthening knowledge on how PPP can be effectively implemented in cancer care. It will present findings from a multi-centre qualitative study conducted in line with the OECI Accreditation and Designation Manual, specifically the chapter on patient involvement and empowerment. Drawing on the perspectives of PPP leads, the study explores how OECI Centres understand, practice and promote PPP. Consequently, key enablers and barriers are identified.

Building on these findings, the session will include an interdisciplinary panel gathering cancer centre directors, PPP coordinators, clinicians, and patient representatives. The panel will reflect on the study results, share best practices, and discuss pathways for strengthening PPP implementation across the network. A brief introduction to AYA is also scheduled.

By the end of the session participants will identify priority actions for advancing meaningful, equitable, and sustainable PPP within OECI Centres.

### Session Outline

**Introduction: Welcome and aims of the session**

*Paulina Bravo*

**The OECI Patient and Public Partnership strategy and work in progress**

*Roxana Plesoianu*

**How are OECI centres implementing Patient and Public Partnerships? Findings from a qualitative study**

*Paulina Bravo and Chiara Pilotti*

**Discussion Panel**

*Moderator: Francesco De Lorenzo*

*Participants: Sophie Beaupère, Alexia Bertuzzi, Caitriona Higgins, Carina Dantas, César Muñoz*

**Closing remarks**

*Paulina Bravo*



June 17

16.30 - 18.30

### Patient-Reported Outcomes in the Digital Age: Advancing Quality of Life Monitoring and Integration in Europe

This session will present the latest developments of the EUonQoL-kit Version 3, the innovative European toolkit designed to measure and monitor the Quality of Life of patient living with and beyond cancer.

A key highlight will be the introduction of the new e-platform developed to enable spontaneous and real-time data collection through the EUonQoL-kit, creating opportunities for dynamic patient engagement and improved data integration across cancer centres and healthcare systems.

Special attention will be given to policy outreach and dissemination activities designed to ensure that EUonQoL outcomes inform European and national cancer policies, with the goal of improving patient-centred care practices.

Through presentations and open discussion, this session will outline how EUonQoL is shaping the future of quality of life monitoring, research translation, and policy integration in the European cancer landscape.

16.30 **Survey Hub: powerful tools to identify and map quality of life inequalities in cancer care**  
*Cinzia Brunelli and Carina Dantas*

16.50 **Q&A / Discussion**

16.55 **Scaling the EUonQoL-kit within the OECI Network and beyond**  
*Katrine Rolid and Caitriona Higgins*

17.15 **Q&A / Discussion**

17.20 **Translating quality of Life data into European cancer policies**  
*Alexandra Eni and Inke Minnée-van Braak*

17.40 **Q&A / Discussion**

17.45 **The next frontier in patient reported outcome assessment: AI-driven and chatbot-based measurement and evaluation**  
*Mogens Groenvold*

18.05 **Q&A / Discussion**

18.15 **Plenary Discussion & Closing Remarks**  
*All Speakers*

June 17

16.30 - 18.30

### Emerging priorities and OECI Working Groups

The OECI is reconceptualising the role and structure of its Working Groups to ensure they reflect the evolving needs of the OECI community and effectively contribute to our shared mission. This session invites members to explore new areas of strategic interest for future WGs-such as precision medicine, biobanking, artificial intelligence, and beyond-with a focus on enhancing engagement in European projects and supporting the OECI Academy. The goal is to shape dynamic WGs with clear objectives that respond to our members' priorities and strengthens OECI's impact across the cancer landscape.

*Moderator: Iwona Lugowska*

16.30 **Introduction**  
*Giovanni Apolone*

16.40 **Precision Medicine**  
*Maud Kamal*

17.00 **Artificial Intelligence**  
*Arsela Prelaj*

17.20 **Biobanks**  
*Olli Carpén*

17.40 **Interactive Session**

18.00 **Questions & Answers**

June 18

08.45 - 10.45

### Session 1

#### New Technology in Primary and Secondary Prevention

This session explores innovative, technology-driven approaches to primary and secondary prevention, from genomics and AI-assisted early detection to population-based HPV vaccination programmes. Experts from leading OECI institutes will discuss how data, digital tools, and precision prevention can reshape European Cancer Networks and policies.

- 08.45 **Opening and Introduction**  
*Chair: Giovanni Apolone and Sławomir Blamek*
- 09.00 **European Code Against Cancer (ECAC5) in Everyday Practice**  
*Paweł Koczkodaj*
- 09.15 **Hyper-early Diagnosis in Oncology and its Clinical Management**  
*Paloma Peinado*
- 09.30 **Large scale identification of individuals with genetic cancer predisposition - biobanks showing the way**  
*Olli Carpen*
- 09.45 **Genetics for the Few, Prevention for the Many – A Pragmatic Playbook for OECI**  
*Suzette Delaloge*
- 10.00 **Reaching the Next Generation – Modern Communication Tools to Shape Healthy Behaviors Among Young People**  
*Wolfgang Fecke*
- 10.20 **Panel Discussion: Scaling Prevention Across Europe From Awareness to System Change**  
*Led by Sławomir Blamek and Giovanni Apolone*  
*Panelists All session speakers*
- 10.45 Coffee Break

June 18

11.00 - 13.00

### Session 2

#### Networking in Oncology – National Models of Collaboration and Excellence in Europe

This session showcases successful national oncology network models across Europe - integrating research, quality assurance, patient pathways and data ecosystems. Speakers will present how coordinated national frameworks enhance outcomes and what lessons can guide emerging networks in Central and Eastern Europe.

- 11.00 **Opening and Introduction**  
*Chair: Simon Oberst and Beata Jagielska*
- 11.05 **Research and Clinical Trial Networks: The UNICANCER Approach**  
*Jean-Yves Blay*
- 11.20 **Patient Pathways and Coordination of Cancer Care: The Dutch Experience**  
*Roos van der Ven*
- 11.35 **Accreditation and Quality Assurance in Oncology: The Italian Model**  
*Ruggiero De Maria*
- 11.50 **Shared Decision-Making on a Policy Level: Lessons from Sweden**  
*Mef Nilbert*
- 12.05 **Building a National Oncology Network in Poland – Challenges and Opportunities in the CEE**  
*Piotr Rutkowski*
- 12.20 **The German Comprehensive Cancer Centres Network – Integration across Hospitals and CCCs**  
*Christian H. Brandts*
- 12.35 **Panel Discussion: National Networks as Engines of Quality and Innovation**  
*Led by Simon Oberst and Beata Jagielska*  
*Panelists: all session speakers*

## OECl Young Network Session

June 18

14.00 - 16.00

At the first session at the OECl Oncology Days led by the Young Board, we will introduce our mission, ongoing initiatives, and our ambitions for the coming years. The focus will be on how junior professionals can actively participate and benefit from our activities across the network.

By emphasizing the value of collaborative activities, including twinning and research grant programmes, we aim to demonstrate how the Young Board can serve as a catalyst for both scientific/clinical career development and improved patient care. The session will include an interactive aspect, where participants are encouraged to share their needs, expectations, and ideas to build the next phase of our network, together.

### Shaping the Future Together: The Young Board's Vision, Actions & Opportunities

Chairpersons: *Evy Lobbestael and Ilkka Liikanen*

- 14.00 **OECl Young Board and Network: Who we are & what we aim for**  
 – *Call Mobility Excellence programme*  
 – *OECl Young Network*  
*Vince Grolmusz and Izabela Agnieszczak*
- 14.35 **The OECl Academy Programme 2026-2028**  
*Carla Finocchiaro*
- 14.45 **Possibilities for collaboration between patients and young professionals**  
*Emmanuelle Hoche*
- 15.00 **Collaboration in action: turning shared efforts into impact**  
 – *DRUP-like clinical trials: working together towards precision oncology*  
*Live Fagereng*  
 – *Improving the outcome of malignant brain tumours with tailored immunotherapy*  
*Pierluigi Calò*  
 – *Engaging students in oncology: a Polish approach (Studenckie Onko-Forum)*  
*Julia Wiktorowska and Paulina Kalman*
- 15.45 **Q&A - roundtable**

## OECl A&D Auditors Session

June 18

14.00 - 16.00

This is a session restricted to auditors and A&D programme staff, and for those cancer centres interested in joining the A&D programme. In the session we will outline current developments in the A&D programme, issues in auditing, and what we can do to improve our processes and data flows.

Speaker: *Simon Oberst and Mef Nilbert*

## CCI4EU Final Report and Expectations on Capacity Building Session CSA Session

June 18

16.30 - 17.30

CCI4EU (Comprehensive Cancer Infrastructures for the EU) concludes in April 2026. In this session we outline the successes and impacts of the 3-year action, and we describe the main interventions in capacity building and their impact: the Deep Dive consultancy interventions; the regional conferences; the online courses, and the observerships. We also describe the Maturity Model adopted, and the manner of evaluating impact through a Global Efficacy Score. We hear some feedback from the CCIs, and then outline the requirements to sustain the progress achieved in the Comprehensive Cancer Infrastructures.

- 16.30 **Introduction to the Action CCI4EU**  
*Maja Čemažar*
- 16.40 **CCI4EU Capacity Building Actions overview**  
*Simon Oberst*
- 17.00 **Online courses, Regional Conference, Deep Dives and Observerships**  
*Simon Oberst and Iva Kirac*
- 17.15 **Sustainable actions including Resources Centre**  
*Maja Čemažar*
- 17.20 **Q&A**

## OECI Participation in the 2026 and 2027 European Commission calls

June 18  
17.30 - 18.30

This session will outline the strategic approach and planned activities of OECI in relation to the 2026 and 2027 European Commission (EC) funding calls. It will present an overview of relevant Horizon Europe work programmes and other EU initiatives that align with OECI's mission to enhance cancer research, innovation, and care quality across Europe. The session will focus on identifying key thematic areas for participation, fostering collaborative opportunities among OECI Members, and strengthening the network's engagement in EU-funded projects. Attendees will gain insights into proposal preparation processes, partnership building, and the mechanisms through which OECI can contribute to and benefit from the forthcoming EC calls, reinforcing its role as a leading actor in the European cancer research and care ecosystem.

Moderator: **Claudio Lombardo**

17.30 **Why EC Calls matter for OECI: How the Network Strengthens European Cancer Research Proposals**

**Giovanni Apolone**

17.45 **HORIZON-MISS-2026-02-CANCER-06 Development of a Research Capacity Building Programme on Cancer with and for Ukraine**

Content focus:

- **Rationale**
- **Objectives**
- **Consortium**

**Vanesa Gregorc**

18.00 **HORIZON-MISS-2027-02-CANCER-04: Improving equitable health outcomes for cancer patients through health-economics research, health systems research and outcomes research**

**Wim H. van Harten**

18.15 **From idea to submission: How OECI members can engage in the selected 2026–2027 EC Calls**

Content focus:

- **Consortium building**
- **OECI Members roles**
- **Time schedule**

**Carla Finocchiaro**

**Discussion**

June 18 - 20.00

## CEREMONY FOR THE DELIVERY OF THE OECI A&D CERTIFICATES June 2025-June 2026

(List to be confirmed)

*Iwona Lugowska and Mef Nilbert*

- Aarhus University Hospital**, Aarhus, Denmark
- Anadolu Medical Center**, Gebze (Kocaeli), Turkey
- ASST Spedali Civili di Brescia (SCH)**, Brescia, Italy
- Cancer Research UK Cambridge Centre**, Cambridge, United Kingdom
- Centre Antoine Lacassagne**, Nice, France
- Centre Jean Perrin**, Clermont-Ferrand, France
- Centre François Baclesse**, Caen, France
- Centre Oscar Lambret**, Lille, France
- Clínic Barcelona Comprehensive Cancer Centre**, Barcelona, Spain
- Fundación Jiménez Díaz University Hospital**, Madrid, Spain
- Institut Bergonié**, Bordeaux, France
- Institut Català d'Oncologia-Hospital Universitari Bellvitge (ICO-HUB)**, Barcelona, Spain
- Institut d'Oncologia de la Catalunya Sud (IOCS) Hospital Universitari Sant Joan de Reus**, Reus, Spain
- Institut du Cancer de Montpellier (ICM)**, Montpellier, France
- Institut Jules Bordet**, Brussels, Belgium
- Istituto Tumori Giovanni Paolo II, IRCCS**, Bari, Italy
- Maria Sklodowska-Curie National Research Institute of Oncology**, Warsaw, Poland
- Rijnstate Oncologisch Centrum**, Arnhem, The Netherlands
- St Vincent's UCD Cancer Centre**, Dublin, Ireland
- The Christie NHS Foundation Trust**, Manchester, United Kingdom



### Draft Agenda

08.00 **Registration**

08.15 **Opening**

**General Assembly Constitution, welcome and approval of the Agenda**  
*Giovanni Apolone*

08.30 **Administrative Session**

*Chairperson: Giovanni Apolone*

**Point 1: Approval of the General Assembly Minutes of 13 June 2025**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Giovanni Apolone*

**Point 2: Approval of the Financial Statement 2025 and discharge to the Board**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Diego Pazienza*

**Point 3: OECI 2026 Provisional Budget**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Alfredo Budillon*

**Point 4: OECI Board composition for the coming years and renewal mandate for one Elected Member**

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

*Giovanni Apolone*

**Point 5: Hand-over of the 2023-2026 Presidency, and transfer of powers to the new Presidency**

(vote not requested)

*Giovanni Apolone and Iwona Ługowska*

**Point 6: New applications/resignation to the OECI membership, proposal of dismissals and requests of exemption from membership fee payment**

(vote requested: for full membership and fee exemption - decision to be taken by unanimity of the OECI Full Members present or represented; for dismissal - decision to be taken by 2/3 of the OECI Full Members present or represented; for associate membership Type A-B-C - decision to be taken by simple majority of the OECI Full Members present or represented; no voting for membership withdrawals).

*Claudio Lombardo*

**Point 7: Proposals for the Oncology Days 2027 and for the coming years**

*Iwona Ługowska*

10.15 **Coffee Break**

### Open Discussion with Members & Close of the 2025

10.30 **Scientific Session**

**The OECI Presidential Strategy**

*Iwona Ługowska*

11.00 **OECIWORLD**

*Thierry Philip*

11.15 **Open discussion with the Members**

*Chairperson: Iwona Ługowska*

12.45 **Closure of the 2026 OECI General Assembly**

13.00 **Lunch**



## Invited speaker

**Izabela Agnieszczak**  
Warsaw, Poland

**Pierluigi Calò**  
Brussels, Belgium

**Carla Finocchiaro**  
Milan, Italy

**Vince Kornél Grolmusz**  
Budapest, Hungary

**Lionel Perrier**  
Lyon, France

**Josep Taberner**  
Barcelona, Spain

**Giovanni Apolone**  
Milan, Italy

**Olli Carpén**  
Helsinki, Finland

**Olive Gallagher,**  
Galway, Ireland

**Astrid Kramer**  
Amsterdam, The Netherlands

**Roxana Plesoianu**  
Brussels, Belgium

**Laura Tack**  
Groening, Belgium

**Sophie Beaupère**  
Paris, France

**Maja Cemažar**  
Ljubljana, Slovenia

**Vanesa Gregorc**  
Turin, Italy

**Ilkka Liikanen**  
Helsinki, Finland

**Thierry Philip**  
Lyon, France

**Léon van Kempen,**  
Maastricht, The Netherlands

**Alexia Bertuzzi**  
Milan, Italy

**Rachel Chown**  
Manchester, United Kingdom

**Mogens Groenvold**  
Copenhagen, Denmark

**Evy Lobbestael**  
Leuven, Belgium

**Chiara Pilotti**  
Rome, Italy

**Jef Vanderroot**  
Leuven, Belgium

**Jean-Yves Blay**  
Lyon, France

**Carina Dantas**  
Coimbra, Portugal

**Neil Grubert**  
United Kingdom

**Claudio Lombardo**  
Genoa, Italy

**Arsela Prelaj**  
Milan, Italy

**Roos van der Ven**  
Utrecht, The Netherlands

**Sławomir Blamek**  
Warsaw, Poland

**Suzette Delalogue**  
Paris, France

**Caitriona Higgins**  
Dublin, Ireland

**Iwona Ługowska**  
Warsaw, Poland

**Camilla Quirland**  
Santiago, Chile

**Wim H. van Harten**  
Amsterdam, The Netherlands

**Christian Brandts**  
Frankfurt, Germany

**Francesco De Lorenzo**  
Rome, Italy

**Emmanuelle Hoche**  
Rouen, France

**Inke Minnee-van Braak**  
Rotterdam, The Netherlands

**Valérie Quevieux**  
Paris, France

**Amaya Villanueva**  
Madrid, Spain

**Paulina Bravo**  
Santiago, Chile

**Ruggero De Maria**  
Rome, Italy

**Beata Jagielska**  
Warsaw, Poland

**César Muñoz**  
Madrid, Spain

**Valesca Retel**  
Amsterdam, The Netherlands

**Susanne Werkman**  
Amsterdam, The Netherlands

**Cinzia Brunelli**  
Milan, Italy

**Alexandra Eni**  
Brussels, Belgium

**Paulina Kalman**  
Warsaw, Poland

**Mef Nilbert**  
Lund, Sweden

**Katrine Rolid**  
Oslo, Norway

**Julia Wiktorowska**  
Warsaw, Poland

**Alfredo Budillon**  
Naples, Italy

**Live Fagereng**  
Oslo, Norway

**Maud Kamal**  
Paris, France

**Simon Oberst**  
Copenhagen, Denmark

**Piotr Rutkowski**  
Warsaw, Poland

**Joanna Williams**  
Manchester, United Kingdom

**Wolfgang Fecke**  
Brussels, Belgium

**Iva Kirac**  
Zagreb, Croatia

**Diego Paziienza**  
Brussels, Belgium

**Michael Schlander**  
Frankfurt, Germany

**Pawel Koczkodaj**  
Warsaw, Poland

**Paloma Peinado**  
Madrid, Spain

**Berit Sunde,**  
Stockholm, Sweden



# OECD2026 ONCOLOGY DAYS

## Warsaw

Warsaw is a dynamic and fast-growing European capital. It is the political, economic and cultural centre of Poland. It is often referred to as the “Phoenix City” because it rose from near-total destruction during the II World War to become a major European centre of culture, science, and business.

June is one of the best months to visit Warsaw, as the city enjoys warm and pleasant weather. Average daytime temperatures range from 20°C to 24°, with longer daylight hours—up to 17 hours of light. Occasional rain showers can occur, but they are usually brief. Parks and river boulevards are in full bloom, and locals spend time outdoors enjoying the mild evenings. It's a perfect time for sightseeing, outdoor cafés, and festivals.



# OECD2026 ONCOLOGY DAYS

## OECD 2026 Gala Dinner

June 18 - 20.00 Hrs

The Gala Dinner of Oncology Days 2026 will be hosted at the Kubicki Arcades in Warsaw, an elegant and historic venue forming part of the Royal Castle complex. Designed in the early 19th century by architect Jakub Kubicki, the arcades originally supported the castle gardens and have since been carefully restored to serve as a distinctive space for cultural and formal events. Situated at the foot of the Royal Castle, between the UNESCO-listed Old Town and the picturesque Vistula River escarpment, the Kubicki Arcades offer a unique combination of history, charm, and a welcoming atmosphere—an ideal setting for our special evening.





## THE OECI 2026 INTERNATIONAL SCIENTIFIC COMMITTEE

### Presidents

Giovanni Apolone and Iwona Lugowska

### Members

Rebecca Amet, Giovanni Apolone, Sławomir Blamek, Christian Brands, Paulina Bravo, Alfredo Budillon, Maja Cemažar, Cinzia Brunelli, Olli Carpén, Steven le Gouill, Vince Kornél Grolmusz, Beata Jagielska, Claudio Lombardo, Iwona Lugowska, Mef Nilbert, Simon Oberst, Júlio Manuel Ramos Maiade Oliveira, Thierry Philip, Janusz Ryś, Per Anders Sandström, Jacqueline M.L. Stouthard, Josep Taberneró Caturla, Wim H. van Harten

## THE OECI 2026 ONCOLOGY DAYS SECRETARIATS

GENOA: Daniela Garbarino, Diana Kochegarova, Alex White

BRUSSELS: Roxana Plesoianu

MILAN: Eleonora De Palo

WARSAW: Agnieszka Janowska

## OECI 2026 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo

[oeци48@oeци.eu](mailto:oeци48@oeци.eu) - [www.oeци.eu](http://www.oeци.eu)



*Under the auspices of:*



Minister of Science and Higher Education  
Republic of Poland

Registration open at:

<https://www.oeци.eu/Assembly.aspx>